Acorda

ACOR NASDAQ
3.120
-0.060
-1.89%
Closed 16:00 08/23 EDT
Open
3.170
Prev Close
3.180
High
3.335
Low
3.110
Volume
1.23M
Avg Vol (3M)
1.31M
52 Week High
29.75
52 Week Low
2.270
% Turnover
2.55%
Market Cap
150.10M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Acorda ACOR stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS). The Company also markets Zanaflex Capsules and tablets, FDA-approved as short-acting drugs for the management of spasticity, and Qutenza, an FDA-approved dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia, also known as post-shingles pain. The Company has a pipeline of neurological therapies addressing a range of disorders, including Parkinson's disease, migraine and MS. The Company's product candidate, CVT-301, is a self-administered inhaled formulation of levodopa.
MORE >

Recently

Name
Price
%Change